8-K
filed June 13, 2023, 7:59 PM ET
ticker PYXS
CIK 0001782223
other
confidence high
sentiment neutral
materiality 0.15
Pyxis Oncology shareholders elect three directors and ratify auditor
Pyxis Oncology, Inc.
- Rachel Humphrey, M.D. elected as Class I director: 13,536,830 for, 3,476,861 withheld, 10,500,726 broker non-votes.
- Freda Lewis-Hall, M.D. elected as Class II director: 13,597,586 for, 3,416,105 withheld, 10,500,726 broker non-votes.
- Thomas Civik elected as Class II director: 13,452,770 for, 3,560,921 withheld, 10,500,726 broker non-votes.
- Ratification of Ernst & Young LLP as FY2023 auditor passed: 27,404,246 for, 80,518 against, 29,653 abstain, no broker non-votes.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Pyxis Oncology, Inc. shareholders approved Election of Rachel Humphrey, M.D. as Class I Director at the 2023-06-13 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-13
Exact text from the filing
Rachel Humphrey, M.D. was elected to serve as a Class I director to hold office until the Company’s 2025 Annual Meeting of Stockholders and until the election and qualification of her successor. Votes were cast as follows: Name of Director Nominee For Withheld Broker Non-Votes Rachel Humphrey, M.D. 13,536,830 3,476,861 10,500,726
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Pyxis Oncology, Inc. shareholders approved Ratification of Appointment of Ernst & Young LLP as Independent Registered Public Accounting Firm for fiscal year ending December 31, 2023 at the 2023-06-13 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-13
Exact text from the filing
The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 by the following vote: For Against Abstain Broker Non-Votes 27,404,246 80,518 29,653 —
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Pyxis Oncology, Inc. shareholders approved Election of Freda Lewis-Hall, M.D. and Thomas Civik as Class II Directors at the 2023-06-13 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-13
Exact text from the filing
Freda Lewis-Hall, M.D. and Thomas Civik were elected to serve as Class II directors to hold office until the Company’s 2026 Annual Meeting of Stockholders and until the election and qualification of their successors. Votes were cast as follows: Name of Director Nominee For Withheld Broker Non-Votes Freda Lewis-Hall, M.D. 13,597,586 3,416,105 10,500,726 Thomas Civik 13,452,770 3,560,921 10,500,726
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.